Saanroo’s PEA Webinar Explores Palmitoylethanolamide as a Novel Approach to Pain and Inflammation Management

Friday, July 10, 2026 – In a significant development for holistic primary care and the broader health industry, a recent webinar hosted by Saanroo, featuring leading chemist Ramasamy V. Venkatesh, has illuminated the potential of palmitoylethanolamide (PEA) as a groundbreaking therapeutic agent for a wide spectrum of pain and chronic inflammation-related conditions. The event, held virtually on July 10, 2026, delved into the scientific underpinnings and clinical applications of PEA, particularly focusing on Saanroo’s proprietary formulation, Levagen®+ powered by LipiSperse® dispersion technology.

The webinar, accessible via recording at https://attendee.gotowebinar.com/recording/4447924113687087274, aimed to equip holistic practitioners with a deeper understanding of PEA’s endogenous role in pain modulation and tissue repair, offering an alternative to conventional pharmaceutical interventions that often carry significant side effects and risks of dependency. The growing prevalence of chronic pain conditions, estimated to affect over 20% of the global adult population according to the World Health Organization, underscores the urgent need for innovative and safe therapeutic strategies. Conditions such as degenerative joint diseases, neuropathic pain, migraines, menstrual disorders, and delayed post-exercise recovery, all common concerns for holistic practitioners, are increasingly being addressed through a more comprehensive understanding of the body’s natural signaling pathways.

The Scientific Foundation of Palmitoylethanolamide

Chemist Ramasamy V. Venkatesh, a seasoned expert with over four decades of experience in the pharmaceutical and nutraceutical sectors, served as the primary presenter. Venkatesh meticulously detailed the multi-receptor mechanism through which PEA exerts its effects. He highlighted PEA’s primary action as an agonist for the peroxisome proliferator-activated receptor alpha (PPAR-α), a key nuclear receptor involved in regulating inflammation and metabolism. Beyond this primary pathway, Venkatesh explained PEA’s indirect modulation of cannabinoid receptors (CB1 and CB2), as well as its interactions with G-protein coupled receptor 55 (GPR55) and transient receptor potential vanilloid 1 (TRPV1) channels.

This complex interplay of receptor activations positions PEA as a unique "parallel endocannabinoid" signaling agent. Unlike traditional cannabinoids, PEA does not directly bind to CB1 receptors in the central nervous system, thus avoiding the psychoactive effects commonly associated with cannabis-based therapies. This distinction is crucial for practitioners seeking to manage pain and inflammation without compromising cognitive function or risking psychological adverse events. The webinar emphasized how this characteristic makes PEA exceptionally well-suited for addressing both peripheral and central pain syndromes, offering a non-intoxicating therapeutic option.

The global market for pain management therapeutics is substantial and projected to grow significantly. Reports indicate that the global pain management drugs market was valued at approximately USD 70 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of over 4.5% from 2024 to 2030, driven by an aging population, the increasing incidence of chronic diseases, and advancements in drug development. However, the limitations of existing opioid-based treatments and concerns over long-term side effects of non-steroidal anti-inflammatory drugs (NSAIDs) are creating a demand for alternative solutions like PEA.

Levagen®+ and the Advancements in Bioavailability

A central theme of the webinar was Saanroo’s Levagen®+ formulation. Venkatesh underscored the critical role of absorption and bioavailability in the efficacy of PEA. Standard PEA preparations can suffer from poor oral bioavailability due to their lipophilic nature and rapid metabolism. To address this, Saanroo has incorporated patented LipiSperse® dispersion technology into Levagen®+. This innovative technology is designed to enhance the dispersion and solubility of PEA in the gastrointestinal tract, leading to significantly improved absorption and, consequently, greater therapeutic impact.

The webinar provided an overview of the development timeline for such advanced delivery systems. The concept of improving the bioavailability of poorly soluble drugs and nutraceuticals has been a focus of pharmaceutical research for decades, with significant advancements in lipid-based formulations, nanoparticle technologies, and improved dispersion techniques emerging over the last 15-20 years. LipiSperse® represents a modern iteration of these efforts, specifically engineered for hydrophobic compounds like PEA.

Clinical Evidence Supporting Levagen®+

Dr. Venkatesh presented a comprehensive review of the clinical research supporting the efficacy of Levagen®+. This included data from multiple randomized, double-blind, placebo-controlled trials, considered the gold standard in scientific evidence. The studies highlighted demonstrated the effectiveness of Levagen®+ in various pain and inflammation-related applications:

• Joint Pain and Stiffness: Clinical trials have shown significant improvements in pain scores and physical function in individuals suffering from osteoarthritis and other forms of joint degeneration. This is particularly relevant as osteoarthritis affects an estimated 303 million people globally, according to the Global Burden of Disease study.
• Acute Menstrual Pain (Dysmenorrhea): Research indicated that Levagen®+ could offer substantial relief from the severe cramping and pain associated with menstruation, a condition that impacts a large percentage of women of reproductive age, with some studies suggesting prevalence rates as high as 80%.
• Migraine: Studies have suggested a role for PEA in reducing the frequency and intensity of migraine headaches, a debilitating neurological condition affecting over 1 billion people worldwide.
• Exercise-Induced Muscle Damage (EIMD): The formulation has demonstrated efficacy in mitigating muscle soreness and accelerating recovery following strenuous physical activity, a significant benefit for athletes and active individuals.

These findings are particularly noteworthy as they address conditions that often have a substantial impact on quality of life and can be challenging to manage with conventional treatments. The ability of Levagen®+ to target the underlying neuroinflammatory pathways offers a more holistic approach to pain management.

Application in Diverse Patient Subgroups

A key takeaway from the webinar was the concept of Levagen®+ as a precision tool rather than a one-size-fits-all supplement. Venkatesh emphasized that its mechanism of action, targeting endocannabinoid-adjacent pathways involved in pain, makes it adaptable for use across a broad range of patient profiles. The webinar aimed to foster a nuanced understanding among practitioners, enabling them to integrate Levagen®+ into personalized treatment plans based on individual patient needs and specific pain etiologies.

The growing trend in personalized medicine, which leverages an individual’s genetic makeup, lifestyle, and environment to tailor healthcare, is directly reflected in the approach advocated for PEA. This shift away from generalized treatments towards targeted interventions represents a significant evolution in healthcare.

Background of Ramasamy V. Venkatesh and Saanroo

Ramasamy V. Venkatesh’s extensive background provides a strong foundation for the insights shared in the webinar. As the founder and managing director of the Gencor Group worldwide, he has been instrumental in developing and launching numerous successful branded products in the global nutraceutical market. His career, spanning over 40 years, encompasses R&D management, scientific reviews, product development, clinical trials, and strategic partnerships. His recognition with the Nutri Champion Award from NutraIngredients in 2024 further solidifies his standing as a leader dedicated to raising industry standards through high-quality, clinically supported ingredients.

Saanroo, as the sponsoring company, is positioned as a key player in advancing the application of scientifically validated ingredients. Their commitment to innovation, exemplified by the LipiSperse® technology, aims to bridge the gap between promising natural compounds and their practical clinical utility. The company’s focus on evidence-based solutions aligns with the increasing demand from both healthcare professionals and consumers for transparent and effective health products.

Broader Impact and Future Implications

The implications of this webinar extend beyond the immediate audience of holistic practitioners. The scientific validation of PEA, particularly in enhanced bioavailability formulations like Levagen®+, could signal a paradigm shift in how chronic pain and inflammation are approached across the healthcare spectrum. As research continues to uncover the intricate mechanisms of endogenous signaling molecules, compounds like PEA offer a promising avenue for developing safer and more effective therapeutic strategies.

The focus on avoiding psychoactive effects also positions PEA favorably in a regulatory landscape that is increasingly scrutinizing cannabinoid-based products. The growing body of clinical evidence is likely to encourage further investigation and potential adoption by mainstream medical practitioners, potentially influencing the future development of pain management protocols.

The success of Saanroo’s Levagen®+ could also spur further innovation in the nutraceutical industry, encouraging other companies to invest in advanced delivery systems for poorly soluble compounds. This, in turn, could lead to a wider availability of potent and bioavailable natural health solutions, benefiting consumers seeking alternatives to conventional pharmaceuticals. The ongoing dialogue between scientific research, industry innovation, and clinical application, as exemplified by this webinar, is crucial for driving progress in the field of integrative health. The event served as a vital platform for disseminating cutting-edge research and fostering collaborative efforts towards improved patient outcomes in pain and inflammation management.